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Key summary points
Aim To examine factors related to resident’s characteristics which are associated with prescribing anti-dementia medicines, atypi-
cal antipsychotics, typical antipsychotics, anxiolytics and other psychostimulants in the individuals with cognitive impairment 
residing in long-term care institutions.
Findings There are still many long-term care (LTC) residents who receive medications that are not recommended or even con-
traindicated in dementia. Despite existing clinical recommendations for treatment of cognitive impairment and neuropsychiatric 
symptoms, the physicians taking care for LTC residents do not follow them properly.
Message Since ca. 70% of LTC residents have cognitive impairment, all physicians taking care of these patients should be 
trained in clinical guidelines of dementia treatment.
Abstract
Purpose To examine factors associated with prescribing anti-dementia medicines (ADM), atypical antipsychotics (A-APM), typi-
cal antipsychotics (T-APM), anxiolytics and other psychostimulants (OP) in the residents of long-term care institutions (LTCIs).
Methods A cross-sectional survey of a country-representative sample of randomly selected LTCIs in Poland, conducted in 2015–
2016. First, we identified 1035 residents with cognitive impairment (CI) among all 1587 residents. Next, we randomly selected 20 
residents from each institution. Study sample consists of 455 residents with CI: 214 recruited from 11 nursing homes and 241 from 
12 residential homes. We used InterRAI-LTCF questionnaire and drug dispensary cards administered on the day of data collection 
to assess use of drugs. Multiple correspondence analysis (MCA), descriptive and logistic regression analyses were performed.
Results The residents were treated with ADM (13.4%), OP (14.3%), antipsychotics (46.4%) including A-APM (24.2%) and 
T-APM (27.9%), and anxiolytics (28.4%). Hydroxyzine was used most often among anxiolytics (71.3%). Prescribing of 
ADM was more likely in Alzheimer’s disease (OR = 4.378; 95%CI 2.173–8.823), while OP in other dementia (OR = 1.873; 
95%CI 1.007–3.485). Administration of A-APM was more likely in older residents (OR = 1.032, 95%CI 1.009–1.055), and 
when delusions appeared (OR = 2.082; 95%CI 1.199–3.613), while there were no neuropsychiatric factors increasing the 
odds of T-APM use. Prescribing of anxiolytics was less likely in moderate CI (by 47.2%) than in residents with mild CI.
Conclusion Current practices of prescribing psychotropics are inadequate in Polish LTCIs, especially in terms of use of 
T-APM and hydroxyzine. More attention should be given to motivate physicians to change their prescribing practices.
Keywords Cognitive impairment · Antipsychotics · Antianxiety agents · Nursing homes · Residential facilities · InterRAI-
LTCF tool
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CI  Cognitive impairment
CMS  The Centers for Medicare and Medicaid 
Services
CPS  Cognitive performance scale
DLB  Lewy body dementia
ICD-code  International classification of diseases
LE  Life expectancy
LTC  Long-term care
LTCI  Long-term care institution
MCA  Multiple correspondence analysis
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NHF  National Health Fund
NMDA  The N-methyl-d-aspartate receptor antagonist
NPSs  Neuropsychiatric symptoms
OP  Other psychostimulants (i.e. medicines 
improving blood perfusion in the brain, but 
not indicated in dementia—N06BX, N07CA)
RH  Residential home
SHELTER  Services and Health for Elderly in Long-
TERm care (SHELTER)
T-APM  Atypical antipsychotic medicines
VaD  Vascular dementia
Introduction
Dementia is a major neurocognitive disorder predomi-
nated by symptoms of cognitive function impairment, 
and often accompanied with neuropsychiatric symptoms 
(NPSs) [1, 2]. Pharmacological treatment of dementia 
essentially focuses on the treatment of these two groups 
of symptoms through the use of anti-dementia (ADM) 
and antipsychotic medicines (APM). During the last 
2 decades, treatment of this disorder evolved towards the 
use of ADM (e.g. donepezil, rivastigmine, memantine) 
and atypical antipsychotic drugs (A-APM) (e.g. quetia-
pine, risperidone, olanzapine), which gradually replace 
nootropic drugs (e.g. piracetam, vinpocetine), typical 
antipsychotics (T-APM) (e.g. haloperidol, promazine) 
and benzodiazepines. The latter, due to side effects, are 
currently not recommended for older people [3]. In light 
of ongoing discussions on the excessive use of medicines 
and the accumulation of adverse effects in older adults, a 
rational approach to treating these disorders in long-term 
care (LTC) residents is particularly relevant. It is also 
important, because the prevalence of cognitive impair-
ment (CI) in these settings is very high, reaching about 
60–70% in most European [4] and Northern American 
countries [5], as well as in Poland [6]. Patients with CI 
are the main group of residents taking psychotropic drugs 
in nonpsychiatric institutions. The way they are treated 
affects not only their quality of life and health status 
[7–9], but also the economic results of the institutions 
they are residing in [10, 11].
In Poland, there are two types of LTC institutions 
(LTCIs): residential homes (RH) served by off-site gen-
eral practitioners (GP) and nursing homes (NH) with 
physicians (with various specializations) employed for 
24 h per 7 days a week. These facilities are organized 
and funded on a different basis (described elsewhere) 
[12], where prescribing and administering of medicines 
are organized differently (supplemental Table 1). Patients 
with CI may be equally referred to RHs and NHs, how-
ever, due to the diverse range of services provided in 
these facilities, treatment of CI may differ between them.
The main aim of this study was to describe the current 
practices of pharmacological treatment of residents with 
CI in LTCIs, with a focus on:
– identifying patterns of inappropriate prescribing in ref-
erence to the level of CI and the type of setting (NH 
and RH), and
– identifying predictors of prescribing specific drugs 
classes.
  To achieve these goals, we have conducted:
– a comparison of use of certain drug classes in light of 
data from international studies;
– a comparison of prescription of anti-dementia medica-
tions (ADM) and treatment with other psychostimu-
lants (OP);
– a comparison of prescription of typical (T-APM) and 
atypical antipsychotic medicines (A-APM);
– a logistic regression analysis to find factors associated 
with administering ADM, T-APM, A-APM, anxiolyt-
ics and OP;
– a multiple correspondence analysis (MCA) to check 
which classes of psychotropic drugs are jointly pre-
scribed in LTC residents depending on the resident’s 




The study was performed in 2015–2016 within 23 LTC 
institutions in Poland, randomly selected in all 6 regions in 
terms of size, status, geographical region, number of beds 
and facility type: NH, which is similar to a skilled nursing 
facility, and RH—a residential facility referring to the clas-
sification proposed by experts’ panel in JAMDA in 2015 
[13]. A detailed description of inclusion criteria to the study 
[6] and a comparison of both types of the facilities have 
been published elsewhere [12]. The study received approval 
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from the relevant University Ethics Committee (decision No. 
122.6120.31.2015).
Study design
From a total of 1587 residents admitted to 23 facilities, we 
excluded 93 individuals who were unable to express any 
cognitive or neuropsychiatric symptoms (NPSs) due to 
indiscernible consciousness or coma. In the first stage of the 
study, we identified 1035 residents with CI based on Cogni-
tive Performance Scale (CPS) [14] score with a cutoff of 2 
points. Next, 20 residents with CI were randomly selected 
from each facility and included in a study group of 455 
residents who were then studied with the interRAI-LTCF 
questionnaire (interRAI Long-Term Care Facilities Assess-
ment System questionnaire)—a validated and widely used 
tool enabling comprehensive geriatric assessment of people 
receiving LTC services [15]. LTC residents were assessed 
by regular staff at each institution—a nurse or a psycholo-
gist—who passed standardized training performed by one 
researcher as specified in the user’s manual of the interRAI-
LTCF tool [16]. The assessments were done mainly on the 
basis of a 3-day observation of the residents, and supported 
(if necessary) by data obtained from medical files, family 
members or other staff. The study protocol and comprehen-
sive characteristics of the study group has been described in 
detail elsewhere [6, 12].
Measurements
A seven-point CPS scale, embedded in interRAI-LTCF 
instrument, was used to assess CI as mild (CPS = 2), mod-
erate (CPS = 3–4) or severe (CPS = 5–6). This is a widely 
used scale [17, 18], which demonstrated a high correlation 
with the Mini-Mental State Examination (MMSE) [14, 19], 
the Montreal Cognitive Assessment (MoCA) [17], and the 
Test for Severe Impairment, nursing judgments of disorien-
tation, and neurological diagnoses of Alzheimer’s disease 
(AD) and other dementias [14] in LTC residents. A seven-
point Activities of Daily Living Hierarchy scale (ADLh), 
measuring functional performance based on four items: 
personal hygiene, locomotion, toilet use and eating, catego-
rized the LTC residents as independent (ADLh = 0–1); mod-
erately dependent (ADLh = 2–3), and severely dependent 
(ADLh = 4–6) [20]. We also applied the four-item Aggres-
sive Behavior Scale (ABS) to measure verbal and physical 
abuse, socially inappropriate behavior, and resistance to 
care, as well as we considered each of these variables sepa-
rately. The ABS ranges from 0 to 12, where a higher score 
indicates a greater frequency of aggressive behavior [21]. 
Depression symptoms were evaluated using the seven-item 
Depression Rating Scale (DRS), which indicates probable 
depression, when its score is 3 and higher [22].
The analyses in this paper were conducted with focus 
on comparing drug use by residents in NHs and RHs. Data 
were collected from drug dispensary cards on the day of data 
collection. We used the Anatomical Therapeutic Chemical 
(ATC) classification [23] to group medicines as following: 
anti-dementia medicines (ADM) (N06DA, N06DX), other 
psychostimulants (OP) (N06BX), atypical antipsychot-
ics (A-APM) (N05AH, N05AX), typical antipsychotics 
(T-APM) (N05AA, N05AB, N05AD, N05AF, N05AL), and 
anxiolytics (N05BA, N05BB, N05CD, N05CF).
Statistical analysis
A detailed list of medications with their use by residents 
depending on the type of institution (RH or NH) is shown in 
Table 2. In the Table 1, we presented relationships between 
the use of selected ATC groups of drugs and the resident 
characteristics (differences were assessed using the  Chi2 
test). In our analyses, we carefully selected the variables 
including: demographic factors (age, gender); type of set-
ting (due to differences in care organization and access to 
physician); severity of CI and level of ADL; factors which 
may trigger use of psychotropic medicines such as: psychotic 
symptoms (hallucinations, delusions), behavior problems 
(agitation, wandering, verbal and physical abuse, resist-
ance to care); depression, psychiatric illness, Alzheimer’s 
disease and other dementia, which may cause indications 
for use of these drugs; and use of restrictive devices as they 
might be associated with administering pharmacologic 
restraints. All these variables were checked consecutively 
in the univariate analysis and logistic regression analysis 
for their associations with the use of drugs from particular 
ATC classes to determine residents’ characteristics associ-
ated with their prescribing (Table 3). The variable of ADL 
level was excluded due to collinearity with the CPS level. 
Some associations occurred to be not straightforward, but 
more complex, and are presented as interactions between 
variables. They are result of careful following the principles 
of performing logistic regression analysis. The way how they 
were calculated had been shown in Table 3, and described 
how they should be interpreted in the results section.
The logistic regression analyses provided information on 
the predictors of prescribing a single drug classes. However, 
in the reality, these drugs are often used together. Therefore, 
we have also carried out a Multiple Correspondence Analy-
sis (MCA) which belongs to a family of descriptive methods, 
that allows to investigate the correlation between several cat-
egorical interdependent variables, measuring the level of iner-
tia among them. It provides a general view of relationships 
between variables when simple cross-tabulations of numerous 
variables become complex and difficult to interpret. We used 
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this analysis to explore the relationships between the use of 
drugs and the variables characterizing the residents (Fig. 1). 
First, we considered information about use of psychotropics 
from particular ATC classes as well as basic characteristics of 
the resident presented in Table 1 (age, gender, type of facility, 
ADL, CPS). Gender and ADL variables had very low val-
ues of discriminatory measures on both dimensions, so they 
were removed from the analysis. We also excluded ADM from 
the MCA, because this variable was strongly correlated with 
presence of Alzheimer’s disease. Finally, we identified two 
dimensions (axes), and seven variables (A-APM, T-APM, 
anxiolytics, OP, LTCI type, level of CI and resident’s age), 
the most correlated with each dimension. In MCA, the squared 
correlations between variables and the dimensions are used as 
coordinates. The distance between any row points or column 
points gives a measure of their similarity (or dissimilarity). 
The variables the most related to each other are focused in a 
group together, whilst dissimilarity, on the other hand, results 
in a distance. Negatively correlated variables are positioned on 
opposite sides of the plot origin (opposed quadrants).
By applying MCA, we explored the correlation between 
use the certain psychotropic drug classes (A-APM, T-APM, 
OP and anxiolytics) in controlling certain resident’s charac-
teristics such as: age, CPS level and facility type. The figure 
above helps to identify seven variables (CI level, resident’s 
age, type of facility, use of drugs from ATC classes: A-APM, 
T-APM, OP and anxiolytics) that are the most correlated 
with each dimension. The squared correlations between 
variables and the dimensions are used as coordinates. The 
distance between any row points or column points gives a 
measure of their similarity (or dissimilarity). Variables that 
make up the group are focused in a group together, whilst 
dissimilarity, on the other hand, results in a distance. Nega-
tively correlated variable categories are positioned on oppo-
site sides of the plot origin (opposed quadrants). Legend: NH 
nursing home, RH residential home, mild CI mild cognitive 
impairment, moderate CI moderate cognitive impairment, 
severe CI severe cognitive impairment, T_APM typical 
antipsychotics, A_APM atypical antipsychotics, OP other 
psychostimulants, ANX anxiolytics. Plus (+) means that the 
patient received a particular drug, whereas minus (−) means 
no usage of particular drug.
Fig. 1  Multiple correspondence 
analysis plot for two dimensions 
of the use of different medica-
tions in LTC residents with 
cognitive impairment (CI) in 
relation to the facility type, resi-
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Analyses were performed with SPSS 25 for Windows. 
Differences were considered statistically significant if p 
value was less than 0.05.
Results
Resident characteristics and use of drugs
The residents with CI in our study were diagnosed for AD 
(ICD-coded with G.30) (12.2%) or other dementia (60.2%) 
(ICD-coded with F01, F02 or F03), had symptoms of depres-
sion (38.6%) or psychiatric diseases other than depression 
and dementia (5.3%). More than 70% residents were female, 
and 42.0% had severe CI, while 88.5% were moderate-to-
severely dependent in ADL (Table 1). They were treated 
with ADM (13.4%), OP (14.3%), any antipsychotics (46.4%) 
and anxiolytics (28.4%). We found that ADM were signifi-
cantly more often administered to RH residents (17.8%) 
than to NH patients (8.4%), while prescribing of A-APM 
was more frequent in older patients at the age 75 years and 
older (approx. 30%). There was no impact of gender, neither 
ADL dependency, nor level of CI on frequency of medication 
use. However, some health conditions (AD, other demen-
tia), symptoms (delusions, agitation), and behavior problems 
(wandering, verbal and physical abuse, resistance to care) 
showed association with significantly higher use of the afore-
mentioned medicines. The use of chair preventing rising was 
associated with almost twice the higher use of A-APM.
The comparison between types of facilities did not show 
significant differences in use of certain drugs classes or sub-
stances with the exception of donepezil, rivastigmine, and 
olanzapine, which were more frequent in RH residents with 
CI (as shown in Table 2). It is worth noting that some of 
the drugs were prescribed more often than the others, e.g. 
donepezil in 7.7% of residents (among ADM), quetiapine 
in 15.4% individuals (among A-APM), perazine (10.1%), 
promazine (7.9%) and haloperidol (7.5%) (among T-APM) 
and hydroxyzine (in 20.2% residents) (among anxiolytics).
Factors associated with prescribing medicines 
from certain therapeutic classes
Upon logistic regression analysis (Table 3), we found that RH 
residents had 2.88 times higher chance to be administered ADM 
(donepezil, rivastigmine or memantine) compared to patients 
in NHs. Moreover, AD (OR = 4.378, 95%CI 2.173–8.823) and 
hallucinations or delusions (OR = 2.244, 95%CI 1.170–4.306) 
significantly increased the chance of taking these drugs.
On the contrary, prescribing of OP (piracetam or vin-
pocetine) was 87% more likely in patients with dementia 
other than AD and almost twice less likely in the residents 
of RHs. Moreover, in RHs, as the age of a resident increases 
by 1 year, the chance they are administered OP increases 
by 4% (the method of calculating the interaction effect is 
shown in Table 3).
We found that dementia other than AD (OR = 1.520, 
95%CI 1.016–2.273) and use of chair preventing rising 
(to protect uncontrolled getting up and fall) (OR = 2.466; 
95%CI 1.272–4.780) were associated with an increased 
use of antipsychotics in general. However, factors associ-
ated with use of typical or atypical antipsychotics differed. 
T-APM were administered to 27.9% of residents, but none of 
the analyzed factors were associated with their prescribing, 
except older age which decreased odds ratio (OR = 0.975; 
95%CI 0.957–0.994). On the contrary, the chance of being 
treated with A-APM (used by 24.2% residents) was sig-
nificantly higher in older patients (OR = 1.032; 95%CI 
1.009–1.055) and individuals with delusions (OR = 2.082, 
95%CI 1.199–3.613). The residents who resisted to care 
had a lower risk (by 54.9%) to be administered A-APM, but 
higher, although not significant risk of receiving T-APM.
Residents with moderate CI were nearly twice less likely 
(by 47.2%) to receive anxiolytics compared to those with mild 
CI. Hydroxyzine was the most often used (71.3%) among 
anxiolytics; therefore, we conducted multivariable regression 
analysis for this single drug. Severe CI (compared to mild 
CI) increased the chance of receiving this drug 2.6 times in 
patients presenting aggressive behavior disorders (assessed 
with ABS). The use of physical restraints (especially full bed 
rails) was high (Table 1). Therefore, we conducted logistic 
regression analysis using them all together as one variable 
and each of them separately, but did not prove their associa-
tion with prescribing of any of analyzed psychotropics class.
Psychotropic drugs prescribing patterns in LTC 
residents
Next, we checked whether there was a correlation between 
the use of selected classes of psychotropic drugs and the 
type of facility, level of CI and resident’s age. By applying 
MCA, we identified two dimensions (axes), which explained 
a 37.06% improved estimate of the inertia among the seven 
factors (CI level, resident’s age, type of facility, use of drugs 
from ATC classes: A-APM, T-APM, OP and anxiolytics). 
For the first factorial axis (axis X), the principal discrimina-
tion measures were associated with LTCI type (0.478) and 
CI level (0.434). For the second axis (axis Y), the discrimi-
nation measures were those mostly associated with using 
or not A-APM (0.470). In the result of MCA, we identified 
three groups of residents. The first group (marked in the 
green circle) consisted of the individuals with severe CI, 
more frequently aged 75–84 years, residing in NH, and tak-
ing OP treatment. The second group (marked with the gray 
circle) contained patients who more often received A-APM 
and anxiolytics but less often T-APM, and that way of treat-
ment was applied mostly to the oldest individuals at the age 
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85 years or older. The third one (marked with the yellow 
circle) included individuals more often taking T-APM, and 
less frequently anxiolytics and A-APM, who were residents 
with moderate CI residing in NH (Fig. 1).
Discussion
Use of anti‑dementia medicines (donepezil, 
rivastigmine, memantine) and other 
psychostimulants
In our study, the use of ADM was less prevalent in Polish 
LTCIs (13.4%) compared to US [24], where 30% of any type 
dementia residents were administered acetylcholinesterase 
inhibitors (AChEIs). It was a little higher than in the Euro-
pean SHELTER study (11.6% residents with severe CI), yet 
our study was conducted 5 years after SHELTER one, when 
prescribing of ADM has become more common. It has been 
improved in our country after including donepezil and trans-
dermal rivastigmine on the “list of drugs for seniors 75+ ” 
allowing patients with AD diagnosis (ICD-coded G30) to 
receive these drugs free of charge, but patients with a diag-
nosis of other dementia (ICD-codes: F01, F02, F03) could 
not get any discount. Therefore, in our study, patients with 
dementia other than AD were more likely to receive cerebral 
vasodilators and nootropic drugs (e.g. piracetam, vinpoce-
tine), despite these medicines not being recommended in 
Table 2  The use of certain medicine substances and drug classes in residents with cognitive impairment in relation to the type of LTC institution
Chi2 test used. Values for which p < 0.05 are highlighted in bold
a ATC the Anatomical Therapeutic Chemical Classification













N06DA02 Donepezil 7.7 (35) 4.7 (10) 10.4 (25) 0.023
N06DA03 Rivastigmine 2.6 (12) 0.5 (1) 4.6 (11) 0.006





N06BX03 Piracetam 8.4 (38) 9.8 (21) 7.1 (17) 0.288





N05AH03 Olanzapine 4.0 (18) 1.4 (3) 6.2 (15) 0.008
N05AH04 Quetiapine 15.4 (70) 15.0 (32) 15.8 (38) 0.810
N05AX08 Risperidone 7.3 (33) 6.1 (13) 8.3 (20) 0.361
Typical antipsychotics 
(N05A)
N05AL01 Sulpiride 1.1 (5) 0.5 (1) 1.7 (4) 0.377
N05AL03 Tiapride 2.2 (10) 2.3 (5) 2.1 (5) 1.000
N05AD01 Haloperidol 7.5 (34) 7.5 (16) 7.5 (18) 0.997
N05AA02 Levomepromazine 1.3 (6) 1.4 (3) 1.2 (3) 1.000
N05AA03 Promazine 7.9 (36) 9.3 (20) 6.6 (16) 0.286
N05AB10 Perazine 10.1 (46) 12.1 (26) 8.3 (20) 0.174
N05AF01 Flupentixol 0.4 (2) – 0.8 (2) 0.501
N05AF013 Chlorprothixene 0.9 (4) 0.5 (1) 1.2 (3) 0.626
N05AF05 Zuclopenthixol 0.7 (3) 1.4 (3) – 0.103
Anxiolytics 28.4% (129) Anxiolytics (N05B) N05BA01 Diazepam 2.0 (9) 3.3 (7) 0.8 (2) 0.090
N05BA04 Oxazepam 0.4 (2) 0.9 (2) – 0.221
N05BA06 Lorazepam 0.9 (4) 0.9 (2) 0.8 (2) 1.000
N05BA12 Alprazolam 1.1 (5) 0.5 (1) 1.7 (4) 0.377
N05BB01 Hydroxizine 20.2 (92) 18.7 (40) 21.6 (52) 0.444
Hypnotics and sedatives 
(N05C)
N05CD02 Nitrazepam 0.7 (3) 0.9 (2) 0.4 (1) 0.603
N05CD04 Estazolam 3.1 (14) 3.3 (7) 2.9 (7) 0.821
N05CD06 Lormetazepam 0.2 (1) – 0.4 (1) 1.000
N05CD07 Temazepam 0.2 (1) – 0.4 (1) 1.000
N05CD08 Midazolam 0.2 (1) – 0.4 (1) 1.000
N05CF01 Zopiclone 0.9 (4) – 1.7 (4) 0.126
N05CF02 Zolpidem 0.9 (4) 0.5 (1) 1.2 (3) 0.626
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Table 3  Factors associated with prescribing psychotropics from certain ATC classes in LTC residents with cognitive impairment—the results of 
univariable and multivariable regression analyses
Univariable logistic regression 
model
Multivariable logistic regression 
model
OR (95% CI) p value OR (95% CI) p value
Anti-dementia medicines
 Facility  typea (NH, ref.) 2.365 (1.318–4.243) 0.004 2.875 (1.491–5.542) 0.002
 Gender (female, ref.) 0.533 (0.274–1.038) 0.064 0.882 (0.412–1.888) 0.747
 Age 1.023 (0.998–1.048) 0.071 1.012 (0.983–1.042) 0.426
 Alzheimer’s disease (No, ref.) 6.085 (3.232–11.457)  < 0.001 4.378 (2.173–8.823)  < 0.001
 Hallucinations or delusions (No, ref.) 2.651 (1.523–4.614) 0.001 2.244 (1.170–4.306) 0.015
 Wandering (No, ref.) 2.243 (1.256–4.006) 0.006 1.154 (0.587–2.265) 0.678
 Mild  CIb (ref.) 1 1
 Moderate  CIb 1.647 (0.791–3.430) 0.182 1.261 (0.557–2.854) 0.578
 Severe  CIb 1.485 (0.781–2.824) 0.227 1.421 (0.687–2.940) 0.343
 Constant 0.014 (0.001–0.169) 0.001
Other psychostimulants
 Facility  typea (NH ref.) 0.676 (0.399–1.147) 0.147 0.537 (0.298–0.967) 0.038
 Gender (female ref.) 0.667 (0.360–1.234) 0.197 0.800 (0.408–1.569) 0.516
 Age (78 years) 1.022 (0.998–1.047) 0.072 0.980 (0.947–1.015) 0.252
 Facility type x Age – – 1.064 (1.011–1.121) 0.018
 Mild  CIb (ref.) 1 1
 Moderate  CIb 1.689 (0.852–3.348) 0.133 1.433 (0.701–2.927) 0.324
 Severe  CIb 1.135 (0.608–2.118) 0.692 0.767 (0.393–1.497) 0.437
 Other dementia (No, ref.) 1.829 (1.023–3.270) 0.042 1.873 (1.007–3.485) 0.047
 Socially inappropriate behavior (No, ref.) 1.376 (0.797–2.375) 0.252 1.428 (0.808–2.525) 0.220
 Constant 0.137 (0.065–0.292)  < 0.001
Effect of interaction: facility type (RH) × age: 1.064 × 0.980 = 1.043. It means a 4% higher chance
Typical antipsychotics
 Facility  typea (NH ref.) 0.696 (0.461–1.050) 0.084 0.761 (0.464–1.246) 0.277
 Gender (female ref.) 0.951 (0.607–1.491) 0.826 0.898 (0.534–1.511) 0.686
 Age 0.981 (0.965–0.998) 0.026 0.975 (0.957–0.994) 0.009
 Mild  CIb (ref.) 1 1
 Moderate  CIb 1.054 (0.596–1.863) 0.856 1.002 (0.551–1.822) 0.995
 Severe  CIb 1.374 (0.961–2.192) 0.183 1.122 (0.661–1.904) 0.669
 Psychiatric  diseasec (No, ref.) 1.576 (0.672–3.700) 0.296 1.526 (0.625–3.729) 0.354
 Agitation (No, ref.) 1.587 (1.026–2.453) 0.038 1.296 (0.769–2.185) 0.330
 Regular contact with family (No, ref.) 1.223 (0.803–1.864) 0.349 1.091 (0.671–1.774) 0.725
 Chair preventing  risinge (No, ref.) 1.710 (0.950–3.081) 0.074 1.394 (0.708–2.743) 0.337
 Wandering (No, ref.) 1.391 (0.865–2.239) 0.174 1.269 (0.745–2.163) 0.380
 Resistance to care (No, ref.) 1.612 (1.051–2.473) 0.029 1.355 (0.812–2.261) 0.246
 Constant 2.190 (0.430–11.165) 0.346
Atypical antipsychotics
 Facility  typea (NH ref.) 1.387 (0.898–2.142) 0.140 1.428 (0.893–2.282) 0.137
 Gender (female ref.) 0.951 (0.593–1.523) 0.833 1.318 (0.773–2.247) 0.310
 Age 1.027 (1.008–1.048) 0.007 1.032 (1.009–1.055) 0.006
 Mild  CIb (ref.) 1 1
 Moderate  CIb 0.874 (0.484–1.581) 0.657 0.745 (0.393–1.412) 0.367
 Severe  CIb 1.041 (0.642–1.688) 0.872 1.195 (0.697–2.049) 0.517
 Psychiatric  diseasec (No, ref.) 1.299 (0.524–3.220) 0.572 1.250 (0.479–3.258) 0.648
 Delusions (No, ref.) 1.755 (1.092–2.820) 0.020 2.082 (1.199–3.613) 0.009
 Wandering (No, ref.) 1.609 (0.987–2.623) 0.057 1.523 (0.882–1.630) 0.131
771European Geriatric Medicine (2020) 11:761–775 
1 3
light of current research, because they are ineffective in both 
vascular dementia (VaD) [25, 26] and Lewy body demen-
tia (DLB) [27]. These findings indicate that prescribing of 
ADM may be suboptimal especially in mild-to-moderate 
stages of dementia. More in depth study is needed to shed 
more light on potential reasons of that, e.g. financial limita-
tions, administrative obstacles, or simply lack of knowledge 
on diagnosis and treatment of dementia.
Use of typical and atypical antipsychotic drugs
Based on a systematic review by Janus et al. [28], the rates 
of use of APM in Western and Nordic European NHs range 
from 12 to 59% with the highest in Austria, Ireland and 
Belgium. In the SHELTER study conducted in 57 NHs in 
8 European countries, 26.4% of all NH residents [29], and 
35.6% of residents with severe CI [30] were treated with 
Values for which p < 0.05 are highlighted in bold
a Facility type (NH nursing home, RH residential home)
b Cognitive performance scale (CPS): mild cognitive impairment (CPS = 2), moderate cognitive impairment (CPS = 3–4), and severe cognitive 
impairment (CPS = 5–6)
c Psychiatric diseases except depression and dementia
d Aggressive Behaviour Scale (ABS): no signs of aggressive behavior (0), any sign of aggressive behaviors (1–12)
e Chair preventing rising: armchair with strips to prevent uncontrolled rising or falling
Table 3  (continued)
Univariable logistic regression 
model
Multivariable logistic regression 
model
OR (95% CI) p value OR (95% CI) p value
 Resistance to care (No, ref.) 0.674 (0.417–1.088) 0.106 0.451 (0.258–0.788) 0.005
 Constant 0.019 (0.003–0.129)  < 0.001
Anxiolitics
 Facility  typea (NH ref.) 1.123 (0.746–1.692) 0.578 1.115 (0.697–1.784) 0.649
 Gender (female ref.) 1.023 (0.656–1.596) 0.920 1.027 (0.620–1.703) 0.917
 Age 1.006 (0.989–1.024) 0.470 1.008 (0.989–1.028) 0.390
 Mild  CIb (ref.) 1 1
 Moderate  CIb 0.573 (0.320–1.026) 0.061 0.528 (0.289–0.966) 0.038
 Severe  CIb 0.893 (0.568–1.405) 0.626 0.796 (0.483–1.312) 0.371
 Agitation (No, ref.) 1.558 (1.011–2.401) 0.044 1.452 (0.882–2.389) 0.142
 Hallucinations (No, ref.) 1.616 (0.954–2.736) 0.074 1.584 (0.888–2.826) 0.119
 Regular contact with family (No, ref.) 0.774 (0.512–1.169) 0.223 0.774 (0.485–1.233) 0.280
 Verbal abuse (No, ref.) 1.972 (1.172–3.317) 0.010 1.358 (0.820–2.252) 0.235
 Constant 0.212 (0.042–1.079) 0.062
Hydroxizine
 Facility  typea (NH ref.) 1.197 (0.755–1.897) 0.445 0.976 (0.559–1.703) 0.931
 Gender (female ref.) 0.968 (0.586–1.599) 0.899 0.957 (0.534–1.715) 0.884
 Age 1.012 (0.992–1.032) 0.242 1.016 (0.993–1.039) 0.187
 Mild  CIb (ref.) 1 1
 Moderate  CIb 0.650 (0.335–1.263) 0.204 0.486 (0.181–1.302) 0.151
 Severe  CIb 1.039 (0.626–1.724) 0.883 0.465 (0.188–1.150) 0.097
 Other dementia (No, ref.) 0.825 (0.519–1.312) 0.417 0.735 (0.443–1.218) 0.232
 Hallucinations (No, ref.) 1.637 (0.921–2.910) 0.093 1.693 (0.880–3.256) 0.115
 Aggressive behaviour (ABS)d (No, ref.) 1.467 (0.922–2.333) 0.106 0.665 (0.288–1.539) 0.341
 Chair preventing  risinge (No, ref.) 0.543 (0.237–1.244) 0.149 0.444 (0.177–1.116) 0.084
 Regular contact with family (No, ref.) 0.577 (0.337–0.988) 0.045
 Mild CI × Aggressive behaviour (ABS) - - 1
 Moderate CI × Aggressive behaviour (ABS) - - 2.528 (0.611–10.454) 0.200
 Severe CI × Aggressive behaviour (ABS) - - 4.591 (1.377–15.300) 0.013
 Constant 0.144 (0.021–0.986) 0.048
Effect of interaction: CI (severe) × aggressive behaviors (yes) (ABS): 0.465 × 4.591 = 2.5998. It means a 2.6 higher chance
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antipsychotics (in 2010). In the US, this percentage was much 
lower than in Europe with tendency to decline—in 14.6% 
of all residents, and 24.8% of dementia patients in NHs (in 
the year 2014) [31]. In light of these data, our results look 
dramatic—antipsychotics were prescribed to 46.4% of RH 
and NH residents with CI. There was only one other study 
on use of these medicines in Poland—it showed similarly 
high rates of antipsychotics use (43.4%) in NH residents with 
moderate and severe dementia (in 2013) [32]. During the 
last decade, the use of A-APM has gradually been replac-
ing typical neuroleptics, nevertheless number of residents 
treated with T-APM is still very high (27.9% in our study), 
even though this class of medicines should be avoided due 
to extrapyramidal and cholinolytic side effects. Multivariable 
regression analysis showed that prescribing A-APM is more 
probable in older residents, and when delusions appear. In 
contrary, there was no factor increasing the odds of T-APM 
use. The last finding may suggest that there is no clear pattern 
of prescribing of these drugs, which may mean that physi-
cians in LTCIs do not follow clinical recommendations.
Use of anxiolytics
Compared to SHELTER study (where 36.0% of residents 
used benzodiazepines), the use of all anxiolytics in our 
LTCIs was lower (28.4% residents) with definitively lower 
usage of long acting benzodiazepines (4.4% of residents 
with CI) and hypnotics (short acting benzodiazepines and 
z-drugs in 6.2% of CI residents). However, 20.2% of stud-
ied residents (71.3% of all individuals taking any anxiolytic 
drug) received hydroxyzine, which according to Beers cri-
teria should be avoided in older patients, especially in AD, 
dementia or other CI. We showed that aggressive behaviors 
in patients with severe CI might increase the risk of admin-
istering this medicine 2.6 times, despite the fact that it is a 
potentially inappropriate drug due to highly anticholinergic 
effects causing risk of confusion and cognitive decline [33]. 
It is worth noting that regular contact with family might 
reduce that risk by almost half.
Use of physical restraints
There is robust literature that physical restraints are measures 
involving deprivation of liberty, which are associated with 
deaths and suppression in quality of life. Nevertheless, in our 
study, the use of restrictive devices as full bed rails was very 
common (57.1%), which is probably caused by the general 
belief of the staff that these are means of protecting the bedrid-
den patients from falling out of bed. The use of other physical 
restraints was much less frequent (5.4% trunk restraints, and 
12.3% chair preventing rising). However, taking into account 
that each use of them is strictly regulated and very limited by 
law, these proportions should be evaluated as relatively high.
We thought that pharmacological and physical restraints 
may be used together or interchangeably in dementia resi-
dents presenting NPS, but statistical analysis did not confirm 
that. We had conducted analysis including use of each type 
of physical restraints (the full bed rails, trunk restraints, chair 
preventing rising) separately and all together as one variable 
in the logistic regression models, however, we did not find 
any significant association between use of them and any of 
psychotropic class.
Drugs prescribing practice in the LTC residents 
with cognitive impairment
As a result of the logistic regression analysis, we have 
received a clear message that Alzheimer’s disease is an 
independent predictor of ADM use, while other dementia 
increases the risk of prescribing OP (nootropic drugs). How-
ever, the level of CI had no impact on use of specific psycho-
tropic drugs with an exception for anxiolytics (odds for their 
use was lower in moderate CI). In contrary, the presence 
of psychotic symptoms or aggressive behaviors increased 
the use of some of psychotropics. Brimelow et al. [34] also 
reported that agitation and psychotic symptoms in residents 
with dementia increased the prescribing of psychotropic 
medicines more than twice. Thus, it seems that the presence 
of certain symptoms is the main trigger to prescribe these 
drugs, not the diseases themselves.
In addition to the regression analysis, which provided us 
with information about determinants of use of certain drug 
classes separately, we examined if there are some classes 
of psychotropic drugs used together (or not). As a result of 
MCA we have gained better insight into how the residents 
with mild, moderate and severe CI are treated in LTCIs. We 
found that taking A-APM was often combined with using 
anxiolytics, but not T-APM, and it applied more often to 
the oldest residents (aged 85 years and older) (a gray circle, 
Fig. 1). In opposite, the residents who were administrated 
with T-APM, more often had moderate CI, and less fre-
quently received A-APM and anxiolytics (a yellow circle, 
Fig. 1). In turn, taking OP was rather correlated with resid-
ing in NH, severe CI and being aged 75–84 years (a green 
circle, Fig. 1). Contrary to that, having mild CI and residing 
in RH was not related to more frequent taking of any psy-
chotropic medications.
Strengths and limitations
This is an epidemiological cross-sectional study, which in 
contrary to longitudinal study design cannot explain cause-
effect relation between symptoms and drugs use. However, 
it is worth highlighting, that this is the first national research 
of the CI residents’ treatment in a country-representative 
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sample of NHs and RHs in Poland conducted with use of a 
tool allowing comparisons with other countries in Europe 
and US. It showed some differences compared with other 
countries (lower use of anxiolytics and much higher use of 
antipsychotics), as well as revealed factors associated with 
taking these drugs. We focused on associations between resi-
dent characteristics and use of drugs from certain classes, 
and found that physicians taking care for LTC residents 
did not follow clinical recommendations for CI treatment, 
properly. We found the differences of prescribing prac-
tices between GPs providing care in RHs and physicians 
employed in NHs, however, due to lack of information about 
their specialties we could not conduct more in depth analysis 
to find if their knowledge and experience had impact on the 
type of treatment.
This paper points out the main treatment issues, which 
should be corrected to assure good quality of care. It pro-
vides some prompts for education of the physicians work-
ing in LTCIs, who often have different specialization back-
ground (not necessarily geriatrics). The rate of geriatricians 
in our country is one of the lowest in EU (0.06 per 1000 
persons at age 65 and over), and most of them work in acute 
geriatric wards. Therefore, physicians working in LTC facili-
ties, both GP and other specialists, definitely need training 
to improve their prescribing practice.
Conclusions
In our study, we examined factors associated with pre-
scribing ADM, A-APM, T-APM, anxiolytics and OP in the 
individuals with CI residing in LTCIs. We found that use 
of ADM was less frequent than in US and in other coun-
tries. Patients with AD had a higher chance of receiving 
ADM, while patients with other dementia—OP. Almost 
half of LTC residents with CI received antipsychotics, 
which is significantly higher than in other European and 
North American countries. In contrary, use of anxiolytics 
was much lower. We found that some NPSs (delusions, 
aggressive behavior), were significantly associated with 
higher use of some psychotropics. Moreover, we have 
observed specific prescribing practices correlated with 
residents’ age, CI level and facility type. We found that 
oldest residents more often used A-APM (compared to 
T-APM) and anxiolytics, while NH residents aged 75–84 
with severe CI more often were prescribed OP. In contrast, 
the residents with moderate CI more often resided in NHs 
and were administered with T-APM.
Our analyses confirmed that there are still many LTC 
residents who receive medications that are not recom-
mended or even contraindicated in dementia (e.g. T-APM 
and hydroxyzine). Despite existing clinical recommenda-
tions for treatment of CI and NPSs, the physicians taking 
care for LTC residents do not follow them properly. Hence, 
more attention should be given to motivate physicians to 
change their prescribing practices to provide residents 
with adequate and effective treatment.
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